AstraZeneca (NASDAQ:AZN) has announced it will shift its US listing from Nasdaq to the New York Stock Exchange, delisting its ...

AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory review after strong trial results.

Astrazeneca (AZN) closed at $94.01 in the latest trading session, marking a -1.21% move from the prior day. This move lagged the S&P 500's daily gain of 0.01%. Elsewhere, the Dow gained 0.55%, while ...

Jan 20 (Reuters) - AstraZeneca on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq ...

Why AstraZeneca is on investors’ radar today AstraZeneca (LSE:AZN) has been drawing attention after a period of solid share price gains. This is prompting investors to reassess how its current ...

Investing.com - Guggenheim has reiterated its Buy rating on AstraZeneca (NASDAQ:AZN) (AZN:LN) with a price target of ...

AstraZeneca AZN stock has risen 15% so far this year compared with an increase of 0.2% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.

Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early ...

The Board of AstraZeneca plc (NASDAQ: AZN) is recommending to shareholders a Harmonized Listing Structure for the company's ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm ...